Gallus BioPharmaceuticals, LLC, a  biopharmaceutical contract development and manufacturing organization, has been selected by Progenics Pharmaceuticals, Inc., a Tarrytown, New York-based pharmaceutical company focused on oncology, to manufacture the anti-prostate specific membrane antigen (PSMA) monoclonal antibody used in Progenics' PSMA antibody drug conjugate product candidate. Under the agreement the antibody will be produced in Gallus' commercial manufacturing facility in St. Louis, Missouri for use in ongoing clinical trials.

Source: Gallus BioPharmaceuticals